$27.85
0.32% yesterday
NYSE, Jan 17, 10:18 pm CET
ISIN
US4330001060
Symbol
HIMS

Hims & Hers Health Inc. Stock price

$27.85
-3.27 10.51% 1M
+5.86 26.65% 6M
+3.67 15.18% YTD
+19.44 231.15% 1Y
+22.56 426.47% 3Y
+17.80 177.11% 5Y
+18.05 184.18% 10Y
NYSE, Closing price Fri, Jan 17 2025
-0.09 0.32%
ISIN
US4330001060
Symbol
HIMS
Industry

Key metrics

Market capitalization $6.08b
Enterprise Value $5.84b
P/E (TTM) P/E ratio 64.42
EV/FCF (TTM) EV/FCF 39.05
EV/Sales (TTM) EV/Sales 4.70
P/S ratio (TTM) P/S ratio 4.90
P/B ratio (TTM) P/B ratio 13.79
Revenue growth (TTM) Revenue growth 56.70%
Revenue (TTM) Revenue $1.24b
EBIT (operating result TTM) EBIT $36.52m
Free Cash Flow (TTM) Free Cash Flow $149.62m
Cash position $254.07m
EPS (TTM) EPS $0.43
P/E forward 52.21
P/S forward 4.17
EV/Sales forward 4.00
Short interest 27.18%
Show more

Is Hims & Hers Health Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,888 stocks worldwide.

Hims & Hers Health Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Hims & Hers Health Inc. forecast:

8x Buy
50%
6x Hold
38%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Hims & Hers Health Inc. forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from Hims & Hers Health Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,242 1,242
57% 57%
100%
- Direct Costs 365 365
131% 131%
29%
877 877
38% 38%
71%
- Selling and Administrative Expenses 827 827
24% 24%
67%
- Research and Development Expense - -
-
-
50 50
252% 252%
4%
- Depreciation and Amortization 14 14
54% 54%
1%
EBIT (Operating Income) EBIT 37 37
187% 187%
3%
Net Profit 101 101
384% 384%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Hims & Hers Health Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hims & Hers Health Inc. Stock News

Negative
The Motley Fool
about 17 hours ago
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m.
Positive
MarketBeat
about 21 hours ago
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Positive
The Motley Fool
2 days ago
Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks to own in healthcare of late.
More Hims & Hers Health Inc. News

Company Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Head office United States
CEO Andrew Dudum
Employees 1,046
Founded 2017
Website www.forhims.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today